Isoenzymes of serum N-acetyl-beta-D-glucosaminidase in the I cell disease heterozygote. 1976

A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen

Serum N-acetyl-beta-D-hexosaminidase is compared quantitatively and qualitatively in 14 obligate heterozygotes for the mutant gene causing I cell disease (ICD) or mucolipidosis II and in 31 normal controls. The average specific activity in either group is significantly different but reliable heterozygote detection cannot be achieved because of some overlapping of the ranges of individual results. Fractionation of the enzyme either by DEAE cellulose column chromatography, or by heat inactivation, yields a typical average result for each genotype. Also, mere expression of the various components as percentages of the total activity is not useful for certain identification of the ICD heterozygote. There is considerable overlapping of the percents hexosaminidase I1 and A in both groups of sera. If enzymatic hydrolysis by any component is expressed as a partial activity, a much better though not absolute distinction between the ICD heterozygote and the normal control becomes possible. Only the latter way of expression of hexosaminidase results makes distinction between the ICD heterozygote and the Tay-Sachs heterozygote very probable.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008064 Lipidoses Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved. Lipidosis,Lipoidosis
D002479 Inclusion Bodies A generic term for any circumscribed mass of foreign (e.g., lead or viruses) or metabolically inactive materials (e.g., ceroid or MALLORY BODIES), within the cytoplasm or nucleus of a cell. Inclusion bodies are in cells infected with certain filtrable viruses, observed especially in nerve, epithelial, or endothelial cells. (Stedman, 25th ed) Cellular Inclusions,Cytoplasmic Inclusions,Bodies, Inclusion,Body, Inclusion,Cellular Inclusion,Cytoplasmic Inclusion,Inclusion Body,Inclusion, Cellular,Inclusion, Cytoplasmic,Inclusions, Cellular,Inclusions, Cytoplasmic
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D004796 Clinical Enzyme Tests Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status. Enzyme Tests, Clinical,Clinical Enzyme Test,Enzyme Test, Clinical,Test, Clinical Enzyme,Tests, Clinical Enzyme
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006596 Hexosaminidases Enzymes that catalyze the hydrolysis of N-acylhexosamine residues in N-acylhexosamides. Hexosaminidases also act on GLUCOSIDES; GALACTOSIDES; and several OLIGOSACCHARIDES. Galactosaminidases,Hexosaminidase,Galactosaminidase,Glucosaminidase,Glucosaminidases
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
February 1992, Clinical chemistry,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
July 1988, Minerva medica,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
September 1986, Clinica chimica acta; international journal of clinical chemistry,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
August 1984, Clinica chimica acta; international journal of clinical chemistry,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
April 1984, Kidney international,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
March 1992, JPMA. The Journal of the Pakistan Medical Association,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
May 1995, Nihon rinsho. Japanese journal of clinical medicine,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
January 1998, Nihon rinsho. Japanese journal of clinical medicine,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
A F Van Elsen, and J G Leroy, and VanneuvilleFJ, and A L Vercruyssen
January 1994, Romanian journal of physiology : physiological sciences,
Copied contents to your clipboard!